Treatment related toxicities with combination BRAF and MEK inhibitor therapy in resected stage III melanoma

Combination dabrafenib (D) and trametinib (T) is an FDA approved adjuvant therapy for patients with resected stage III BRAF-mutant melanoma. We describe treatment-related toxicities with adjuvant D+T in a real-world population through a retrospective case series. The primary endpoint was development...

Descripción completa

Detalles Bibliográficos
Autores principales: Homan, Morgan, Warrier, Govind, Lao, Christopher D., Yentz, Sarah, Kraft, Shawna, Fecher, Leslie A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538392/
https://www.ncbi.nlm.nih.gov/pubmed/36212431
http://dx.doi.org/10.3389/fonc.2022.855794

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538392/
https://www.ncbi.nlm.nih.gov/pubmed/36212431
http://dx.doi.org/10.3389/fonc.2022.855794

Ejemplares similares